AngioDynamics, Inc.: financial statements

ANGONASDAQHealthcare · Surgical & Medical Instruments & Apparatus

Price

$11.87

November 13, 2026Market cap $499M

What Ploutos Investor adds for AngioDynamics

Part of Ploutos Investor, €9.99 a month

See the plans
  • The full history: 17 fiscal years, from FY2010
  • The estimated fair value, with its range and its certainty
  • The full analysis, 18 a month
  • More questions to the chat on its filings
  • Excel with every year
  • An email when it reports, changes its dividend or an officer buys

Sign in with a free account to see the last 5 fiscal years.

Financial statements

Each fiscal year's income statement, balance sheet and cash flow as the company filed them, and the latest quarters.

FY2024–FY2026 fiscal years

Click a line to see it on the chart.

Revenue

LineFY2024FY2025FY2026Average a year
Revenue $304M$292M$320M
Cost of revenue $149M$135M$145M
Gross profit $155M$158M$175M
Operating income -$192M-$40M-$40M
Net income -$184M-$34M-$37M
Earnings per share -$4.59-$0.83-$0.88
Earnings per share, basic -$4.59-$0.83-$0.88
Margins
Gross margin 50.9%53.9%54.6%
Operating margin -63.3%-13.7%-12.5%
Net margin -60.7%-11.6%-11.5%

Financial statements

ANGO's revenue, profits and cash flows from FY2010 to FY2023, 14 more fiscal years

Part of Ploutos Investor, €9.99 a month

See the plans

Sign in with a free account to see the last 5 fiscal years.

By segment

Revenue and operating income by business segment or by product, as the company itself reports them in each year's 10-K. Each year from the latest filing that carries it, so a segment renamed or re-cut shows in its current form.

  • FY2024: Med Device $198M, Med Tech $106M
  • FY2025: Med Device $166M, Med Tech $127M
  • FY2026: Med Device $170M, Med Tech $150M
SegmentFY2024FY2025FY2026Share FY2026
Med Device$198M$166M$170M53%
Med Tech$106M$127M$150M47%

By segment

ANGO's revenue by segment from FY2023 to FY2023, 1 more fiscal year

Part of Ploutos Investor, €9.99 a month

See the plans

Sign in with a free account to see the last 4 fiscal years.

From the XBRL of 13 of the company's annual reports to the SEC (ASC 280). Amounts in dollars.

Amounts are in dollars as the company filed them in its annual reports (10-K or 20-F). Those reporting in another currency are converted at each fiscal year-end rate. Shares and earnings per share are adjusted for splits.

Debt and obligations

What the company owes beyond the loans on its balance sheet, and when it pays, from the notes to its annual report: debt maturities, leases, pension plans, goodwill by segment, and how it gets to the tax it pays.

$11M Leases-1.2% Effective tax rate

Leases

May 31, 2026

Operating leases

$5.2M

Finance leases

$5.8M

The liability is the present value of the rent still to pay, at May 31, 2026. It is not counted in the ladder's debt. The filing

From the statutory to the effective tax rate, FY2026

May 31, 2026

Statutory rate

21.0%

Effective rate

-1.2%

-22.2 pts

The company paid -1.2% in tax on its profit, 22.2 points below the US federal rate (21.0%). Below, the reasons it gives.

Statutory rate

21.0%

Change in valuation allowance

-17.8 pts

Difference the filing does not itemize

-4.4 pts

Effective rate

-1.2%

One point is 1% of profit before tax. The lines are as the company states them in the notes to its annual report. The filing

Earnings quality

How the reported earnings were made, read from the filings. A description, not a score: our tests found no link between these measures and later share returns.

Receivables and inventory against sales

In the quarter to Aug 31, 2026, sales were +6.9% on the same quarter a year earlier, and receivables +5.3%. Inventory was -11.7%, against -2.9% for the cost of sales.

a year earlier 51 days
51 days
a year earlier 167 days
152 days

Balances at Aug 31, 2026 and Aug 31, 2025, against the sales and cost of sales of the quarter ending on each date; a fourth quarter is the fiscal year less its first nine months. Same quarter against same quarter, so the season is the same.

Allowance for doubtful accounts

The allowance for receivables that may not be collected was 3.7% of gross receivables at Aug 31, 2026, against 4.8% a year earlier.

At last year's share it would be $504.8K larger. A smaller allowance means a smaller charge for bad debts in profit.

  • The share fell more than at nine in ten S&P 500 companies that report it.
a year earlier $2.2M
$1.7M

Taxes: deferred and paid

The deferred part was 32.4% of the tax charge in the year to May 31, 2026.

Cash taxes paid were 135.5% of the current tax charge in the year to May 31, 2026.

Deferred share, year to May 31, 2026$143.0K of $442.0K
32.4%
$405.0K paid, $299.0K current
135.5%

When profit in the accounts runs ahead of taxable profit, the deferred part grows. It also moves for reasons unrelated to how earnings are booked: tax-law changes, the use of past losses, and the US rule since 2022 that spreads research costs over five years. Where the notes report it, the tax-rate bridge under Debt and obligations shows how the rate gets from the statutory one to the effective one.

The earnings per share split is not shown: it needs a profit before tax in both years, since a tax rate on a loss has no meaning as a source.

A reading is called out when it is above the 90th percentile of the same reading across the S&P 500, or, for a fall, below the 10th, as measured on 9 November 2026. Each part uses only the company's own filings.

The full analysis

What do AngioDynamics's filings show?

These are AngioDynamics's figures from its filings. The full Ploutos AI analysis reads everything the company has filed and shows what stands behind it, with a source for every figure.

  • A fair value range built from the filings
  • Earnings quality, debt and red flags
  • Insider and institutional moves
  • The case for and the case against

Questions about ANGO's financials

Didn't find what you were looking for?

Ask us
How much revenue did ANGO have in FY2026?

AngioDynamics had revenue of $320M and net income of -$37M in fiscal FY2026, a net margin of -11.5%.

How much debt does ANGO have?

On May 31, 2026 AngioDynamics had total assets of $267M, debt of – and shareholders' equity of $171M.

How much free cash flow does ANGO have?

In fiscal FY2026 AngioDynamics had cash from operations of $3.1M and spent $2.6M on capital expenditure, leaving $508.0K of free cash flow.

Where are the figures from?

From AngioDynamics, Inc.'s annual and quarterly reports to the SEC, read from the structured data (XBRL) it files itself.

Related pages

The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.

The figures come from the company's SEC filings and the share price, and describe what it has reported. They are not a score or a fair value.